PPT-COVID-19/SARS-CoV-2 & back to school

September 3 2020 Dr Dawn Bowdish PhD Canada Research Chair in Aging amp Immunity McMaster University bowdishmcmasterca wwwbowdishca Twitter amp Instagram MsMacrophage . Page 9 Yan Leyfman 1 , Timothy K. Erick 1 , Pushpa Sharma 1,2 1 WACEM-ACAIM Joint Global COVID-19 Taskforce— Immunology Division, USA 2 Department of Anaesthesiology, Uniformed Services Universit 2 In the event that the medical doctor confirms it arrangements must be made with the Mobile Emergency so that the employee with symptoms quickly leaves the Plant and the family and the corresponding One Health Partners Monthly COVID-19 WebinarCoordinated by the CDCOne Health Office in partnership with the One Health Federal Interagency COVID-19 Coordination OH-FICC GroupOne SARS-CoV-Updated 3/2/2020Samuel R Dominguez MD PhD and Ann-Christine Nyquist MD MSPH1What is the SARS-CoV-2and where did it come fromSARS-CoV-2 previously called 2019 novel coronavirusis a coronavirus The more the virus circulates, the more the virus will evolve
Most changes have little to no impact on the virus’s properties or behaviour
However, some changes to SARS-CoV-2 lead to the emergence of variants that may affect: David J. Weber, MD, MPH, FIDSA, FSHEA, FRSM (London). Sanders Distinguished Professor of Medicine, Pediatrics and Epidemiology. Associate Chief Medical Officer. Medical Director, Hospital Epidemiology. Webinar presenters:. Robert Davenport, MD University of Michigan . (rddvnprt@med.umich.edu). Alesia Kaplan, MD University of Pittsburgh . (akaplan@itxm.org). Hua Shan, MD Stanford University . (hshan@stanford.edu). 1614 calculations need be made using demo graphic and epidemiological data. For example, with the recorded case fatality rates in the UK during the rst COVID-19 wave and with the UK demography, - CoV - 2 Patricia Slev, PhD, D(ABCC) Section Chief, Immunology, ARUP Laboratories Associate Professor, University of Utah School of Medicine patricia.slev@aruplab.com 1 DISCLOSURES P Slev None OBJEC *AddresscorrespondencetoGowriKaruppasamy,InternalMedicineDepartment,HamadMedicalCorporation,AlRayyanRoad,POBox3050,Doha,Qatar.E-mail:gkaruppasamy@hamad.qa cantinvestigationsincludedlipaseof�1,2 Nimalie D. Stone, MD. Long-term Care Team Lead. Kara M. Jacobs Slifka, MD. Long-term Care Team. Nursing Home COVID-19 Action Network Conversation Series. Financial Disclosures. No disclosures to report.. Constance A. Benson, MD. Professor of Medicine and Global Public Health. University of California San Diego. La Jolla, California. Financial Relationships With Commercial Entities. Dr Benson has served on advisory and data safety monitoring boards for GlaxoSmithKline/ViiV Healthcare, received research grants awarded to her institution from Gilead Sciences, Inc., and serves as a consultant to NDA Partners, LLC. Her spouse has served as a consultant to . 03 February 2021. Dr B Semete. Contents. COVID-19 vaccines. Ivermectin. access program. Summary of the most advanced vaccines in development. Vaccine applications submitted to SAHPRA. Vaccine developer. (virus). Guam Department of Public Health and Social Services. Disclaimer: This is a rapidly evolving situation. Information and guidance are constantly changing. Information presented in these slides may already be out-of-date..